Scientific Evidence

Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Aug 2017

Prospective evaluation of the GEP performance in patients enrolled in two clinical registries for three primary endpoints recurrence-free (RFS), distant metastasis-free (DMFS), and overall survival (OS).

Author: Hsueh E, et al.

Publication: Journal of Hematology and Oncology

Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists clinical management decisions

May 2017

Risk appropriate management recommendations for implementing SLNB and imaging were more likely to be made following incorporation of DecisionDx-Melanoma test results.

Author: Farberg A, et al.

Publication: Journal of Drugs and Dermatology

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer individualized melanoma patient outcome prediction tool with a 31-gene expression profile–based classification

May 2017

Comparison and accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.

Author: Ferris L, et al.

Publication: Journal of the American Academy of Dermatology

Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients

May 2016

Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).

Author: Berger A, et al.

Publication: Current Medical Research and Opinion

Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy

Mar 2015

Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients.

Author: Gerami P, et al.

Publication: Journal of the American Academy of Dermatology

Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma

Jan 2015

Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS, DMFS, MSS, OS using Kaplan-Maier analysis.

Author: Gerami P, et al.

Publication: Clinical Cancer Research